Net loss was $43.4 million, or $0.29 per share, compared to $41.6 million, or $0.31 per share, in the prior-year period.
Operating expenses rose to $56.6 million from $48 million
last year, mainly due to a $19.3 million restructuring charge resulting from
operational changes. R&D expenses fell to $28.6 million from $38.7 million,
mainly due to lower personnel expenses.
For the full year of 2019, the company expects revenues of
$40-45 million and operating expenses of $175-180 million.
During the second quarter, ImmunoGen accelerated enrollment in
the FORWARD II mirvetuximab plus bevacizumab combination cohort in
ovarian cancer patients for whom a non-platinum-based regimen would be an
appropriate next therapy. The company expects to complete
enrollment in the FORWARD II mirvetuximab plus bevacizumab combination cohort
in the third quarter.
ImmunoGen plans to initiate the Phase 3 registration study
of mirvetuximab as a monotherapy for women with FRα-high, platinum-resistant
ovarian cancer by the end of this year and also to commence enrollment in the
IMGN632 combination and single-agent MRD+ Phase 2 cohorts.
ImmunoGen had $239.8
million in cash and cash equivalents as of June
30, 2019. Capital expenditures were $2.4
million for the first half of 2019.
ImmunoGen’s stock has dropped 49% year-to-date and 4% in the past three months.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.